Brokerages Set Tempus AI, Inc. (NASDAQ:TEM) PT at $56.36

Tempus AI, Inc. (NASDAQ:TEM) has been given an average rating of “Moderate Buy” by the twelve research firms that are covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $56.36.

Several research analysts have issued reports on TEM shares. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Bank of America lifted their target price on shares of Tempus AI from $52.00 to $54.00 and gave the stock a “neutral” rating in a research note on Friday, December 13th. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a “buy” rating and a $74.00 target price for the company. Piper Sandler reissued a “neutral” rating and set a $70.00 price target (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Finally, Wolfe Research assumed coverage on shares of Tempus AI in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company.

Tempus AI Price Performance

Shares of Tempus AI stock opened at $50.77 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI has a 1 year low of $22.89 and a 1 year high of $79.49. The firm’s 50-day moving average is $44.11 and its two-hundred day moving average is $47.97.

Insider Activity at Tempus AI

In other news, CEO Eric P. Lefkofsky sold 85,788 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $53.39, for a total transaction of $4,580,221.32. Following the transaction, the chief executive officer now owns 5,771,787 shares of the company’s stock, valued at approximately $308,155,707.93. The trade was a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Ryan Fukushima sold 120,000 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the completion of the sale, the chief operating officer now owns 1,007,207 shares in the company, valued at approximately $42,816,369.57. This trade represents a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 1,862,758 shares of company stock valued at $79,585,675.

Institutional Trading of Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Apollon Wealth Management LLC purchased a new stake in Tempus AI in the 4th quarter valued at about $256,000. Sumitomo Mitsui Trust Group Inc. increased its stake in Tempus AI by 166.0% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company’s stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Tempus AI during the fourth quarter worth about $178,000. James J. Burns & Company LLC purchased a new stake in Tempus AI during the fourth quarter worth about $236,000. Finally, abrdn plc purchased a new stake in Tempus AI during the fourth quarter worth about $2,784,000. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.